BIO vs MOG.A
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BIO · Bio-Rad Laboratories$381.57 ▲ 3.41%
MOG.A · Moog-A$323.56 ▲ 4.87%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BIO +24.1%
- MOG.A +58.9%
Head to head
| Metric | BIO | MOG.A |
|---|---|---|
| Price | $381.57 | $323.56 |
| Change today | ▲ 3.41% | ▲ 4.87% |
| Market cap | $10.26B | $10.25B |
| Return, 3 months | +7.6% | -21.0% |
| Return, year to date | +25.9% | +33.2% |
| Return, 1 year | +24.9% | +61.2% |
| P/E (TTM) | 10.1 | 27.5 |
| P/B | 1.3 | 4.6 |
| P/E percentile vs own 5y | 93rd | 67th |
| Dividend yield | – | 0.36% |
| Revenue growth (YoY, latest qtr) | -0.1% | +15.2% |
| Net profit growth (YoY) | +16.9% | +159.9% |
| Gross margin | 51.9% | 28.2% |
| Operating margin | 8.7% | 12.1% |
| Net margin | 8.6% | 8.7% |
| Return on equity | 3.1% | 18.1% |
| Analyst target vs. price | +2.2% | +37.7% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 56 | 38 |
| 30-day volatility | 34.8% | 52.2% |
| Max drawdown, 1 year | -28.1% | -30.7% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BIO is the largest of the group by market value.
- MOG.A has returned the most over the past year.
- BIO carries the lowest trailing P/E.
- MOG.A is growing revenue fastest.
- MOG.A keeps the most profit per dollar of sales.
- BIO has been the calmest stock over the last 30 days.